Selecta chooses Takashi Kei Kishimoto for CSO
This article was originally published in Scrip
Selecta Biosciences, a biopharmaceutical company developing novel targeted vaccines and immunotherapies, has appointed Dr Takashi Kei Kishimoto chief scientific officer reporting to Dr Werner Cautreels, Selecta's CEO. Dr Kishimoto most recently served as vice-president of research at Momenta Pharmaceuticals, where he led a team advancing novel and complex generic products for inflammation, oncology and cardiovascular disease.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.